

Tallinn, 18 April 2025

To: 25th WHO Expert Committee on Selection and Use of Essential Medicines
EML Secretariat
emlsecretariat@who.int

Subject: "A.19 Methylphenidate – attention deficit hyperactivity disorder"

This letter confirms the support of the Board of ATH Liit (ADHD Estonia) for the addition of methylphenidate-based medication to the WHO Essential Medicines List, as detailed in "A.19 Methylphenidate – attention deficit hyperactivity disorder."

ADHD medication based on the active ingredient methylphenidate has long been proven to be an effective treatment option for both children and adults.

Given the extensive research available, we believe it is time to include methylphenidate in the WHO Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc).

Respectfully,



Tanel Peets
Board member of ADHD Estonia